Molecular Partners AG
SIX:MOLN
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
B
|
Beijing LabTech Instruments Co Ltd
SSE:688056
|
CN |
Molecular Partners AG
Long-Term Debt
Molecular Partners AG
Long-Term Debt Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Long-Term Debt | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
|
Molecular Partners AG
SIX:MOLN
|
Long-Term Debt
CHf2.4m
|
CAGR 3-Years
-13%
|
CAGR 5-Years
-17%
|
CAGR 10-Years
N/A
|
|
|
CRISPR Therapeutics AG
NASDAQ:CRSP
|
Long-Term Debt
$0
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Basilea Pharmaceutica AG
SIX:BSLN
|
Long-Term Debt
CHf75.4m
|
CAGR 3-Years
-17%
|
CAGR 5-Years
-21%
|
CAGR 10-Years
-9%
|
|
|
Idorsia Ltd
SIX:IDIA
|
Long-Term Debt
CHf1.2B
|
CAGR 3-Years
1%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Kuros Biosciences AG
SIX:KURN
|
Long-Term Debt
CHf4.3m
|
CAGR 3-Years
42%
|
CAGR 5-Years
16%
|
CAGR 10-Years
N/A
|
|
|
Relief Therapeutics Holding SA
SIX:RLF
|
Long-Term Debt
CHf1.5m
|
CAGR 3-Years
-14%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Molecular Partners AG
Glance View
Molecular Partners AG engages in the development of protein therapies for treatment of serious diseases like cancer and sight-threatening disorders. The company is headquartered in Schlieren, Zuerich and currently employs 163 full-time employees. The company went IPO on 2014-10-22. The firm has formed partnerships with leading pharmaceutical companies to advance DARPin therapeutics , and has compounds in various stages of clinical and preclinical development across multiple therapeutic areas.
See Also
What is Molecular Partners AG's Long-Term Debt?
Long-Term Debt
2.4m
CHF
Based on the financial report for Dec 31, 2025, Molecular Partners AG's Long-Term Debt amounts to 2.4m CHF.
What is Molecular Partners AG's Long-Term Debt growth rate?
Long-Term Debt CAGR 5Y
-17%
Over the last year, the Long-Term Debt growth was 99%. The average annual Long-Term Debt growth rates for Molecular Partners AG have been -13% over the past three years , -17% over the past five years .
